V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

SpringWorks Therapeutics Executive Compensation (FY24)

SWTX · Executive and director compensation, fiscal 2022 to 2024

The SpringWorks Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): May 14, 2025
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
SpringWorks Therapeutics brief$1,500Get the executive brief
257 figures on this page: 252 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Chief executive, fiscal 2024
◇
Saqib Islam
Latest say-on-pay support
=
May 14, 2025
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Saqib Islam: $18,351,489 → $16,153,317 (12.0% lower)
Say-on-pay support: 58.0% → 93.7% (35.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is SpringWorks Therapeutics' chief executive and what were they paid?
Saqib Islam was paid $16,153,317 in total compensation as Chief Executive Officer for fiscal 2024. Islam's total moved 12.0% lower from the $18,351,489 reported for fiscal 2023.
What was SpringWorks Therapeutics' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 93.7% of votes cast for or against in favor at the meeting held May 14, 2025.
Which companies are in SpringWorks Therapeutics' peer group?
The disclosed peer group names ACADIA Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Arvinas, Inc., among others.
What is SpringWorks Therapeutics' chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 36:1, against median employee compensation of $454,858.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Saqib Islam
Chief Executive Officer
◇—◇◇◇—◇◇
Badreddin Edris
Chief Operating Officer
◇—◇◇◇—◇◇
Bhavesh Ashar
Chief Commercial Officer
◇—◇◇◇—◇◇
Francis Perier
Chief Financial Officer
◇—◇◇◇——◇
James Cassidy
Chief Medical Officer
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Saqib Islam
Chief Executive Officer
◇—◇◇◇—◇◇
Badreddin Edris
Chief Operating Officer
◇—◇◇◇—◇◇
James Cassidy
Chief Medical Officer
◇◇◇◇◇—◇◇
Francis Perier
Chief Financial Officer
◇—◇◇◇——◇
Bhavesh Ashar
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Saqib Islam
Chief Executive Officer
◇—◇◇◇—◇◇
Badreddin Edris
Chief Operating Officer
◇—◇◇◇—◇◇
James Cassidy
Chief Medical Officer
◇—◇◇◇—◇◇
Bhavesh Ashar
Chief Commercial Officer
◇—◇◇◇—◇◇
Francis Perier
Chief Financial Officer
◇—◇◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Badreddin EdrisRSU◇——◇——◇
Badreddin EdrisOPTION◇——◇—◇◇
Bhavesh Ashar M.B.A.OPTION◇——◇—◇◇
Bhavesh Ashar M.B.A.RSU◇——◇——◇
Francis I. Perier Jr. M.B.A.OPTION◇——◇—◇◇
Francis I. Perier Jr. M.B.A.RSU◇——◇——◇
James CassidyRSU◇——◇——◇
James CassidyOPTION◇——◇—◇◇
Saqib IslamRSU◇——◇——◇
Saqib IslamPSU◇—◇◇◇—◇
Saqib IslamOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Saqib IslamPSU◇◇——
Option◇—◇1/5/2033
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇1/7/2031
Option◇—◇1/4/2034
Option◇—◇1/6/2032
RSU◇◇——
James CassidyRSU◇◇——
Option◇—◇9/1/2031
Option◇—◇1/4/2034
RSU◇◇——
RSU◇◇——
Option◇—◇1/6/2032
Option◇—◇1/5/2033
Bhavesh AsharOption◇—◇10/11/2032
Option◇—◇1/5/2033
Option◇—◇1/4/2034
Option◇—◇1/6/2032
Option◇—◇4/1/2031
RSU◇◇——
RSU◇◇——
RSU◇◇——
Francis PerierOption◇—◇1/7/2031
Option◇—◇1/5/2033
RSU◇◇——
Option◇—◇1/4/2034
Option◇—◇1/6/2032
RSU◇◇——
RSU◇◇——
Badreddin EdrisOption◇—◇1/6/2032
Option◇—◇1/5/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/7/2031
Option◇—◇1/4/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Martin Mackay
◇◇◇———◇
Daniel S. Lynch
Board chair
◇◇◇———◇
Julie Hambleton
◇◇◇———◇
Alan Fuhrman
◇◇◇———◇
Carlos Albán
◇◇◇———◇
Saqib Islam and Freda Lewis-Hall served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options.
Stock ownership guideline: 4x annual board cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Agios Pharmaceuticals, Inc. AGIO
  • Apellis Pharmaceuticals, Inc. APLS
  • Arcus Biosciences, Inc. RCUS
  • Arvinas, Inc. ARVN
  • Blueprint Medicines Corp. BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Immunovant, Inc. IMVT
  • Iovance Biotherapeutics, Inc. IOVA
  • Revolution Medicines, Inc. RVMD
  • Sarepta Therapeutics, Inc. SRPT
  • TG Therapeutics, Inc. TGTX
  • Ultragenyx Pharmaceutical, Inc. RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 14, 2025=◇◇◇
2023May 16, 2024=◇◇◇
2022May 24, 2023=◇◇◇
2021May 19, 2022=◇◇◇
2020May 20, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when SpringWorks Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact SpringWorks Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where SpringWorks Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether SpringWorks Therapeutics' disclosed peer group is defensible, who names SpringWorks Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
257 figures on this page: 252 cited to the filing that reported them, 5 calculated from figures it prints.
252 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001104659-25-048608
  2. 0001104659-25-032187
    2024 Non-Employee Director Compensation Table · CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · and 2 more sections
  3. 0001104659-24-063076
  4. 0001104659-24-044252
    Summary Compensation Table
  5. 0001104659-23-064623
  6. 0001104659-23-043138
    Summary Compensation Table
  7. 0001104659-22-063374
  8. 0001104659-21-071161
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “SpringWorks Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/SWTX (accessed 2026).
Short form: data: Velarion

The SpringWorks Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about SpringWorks Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers SpringWorks Therapeutics discloses

The companies named in SWTX's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Agios Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.Arcus Biosciences, Inc.Arvinas, Inc.Blueprint Medicines Corp.BridgeBio Pharma, Inc.Deciphera Pharmaceuticals, Inc.Immunovant, Inc.Iovance Biotherapeutics, Inc.Revolution Medicines, Inc.Sarepta Therapeutics, Inc.TG Therapeutics, Inc.Ultragenyx Pharmaceutical, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy